RENOVARO INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.13 USD | -5.83% |
|
-24.67% | -64.35% |
| Apr. 24 | Renovaro's RenovaroCube Amends Agreement to Acquire 100% Stake in Cyclomics | MT |
| Apr. 18 | Renovaro Inc. Announces Geert Kazemier, MD, PhD, as the New Chairman of its Scientific Advisory Board | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2022 | - | Sales 2023 | - | Capitalization | 34.41M |
|---|---|---|---|---|---|
| Net income 2022 | -113M | Net income 2023 | -39M | EV / Sales 2022 | - |
| Net cash position 2022 | 1.99M | Net Debt 2023 | 3.9M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-0.89
x | P/E ratio 2023 |
-0.8
x | Employees | 12 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 73.77% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -5.83% | ||
| 1 week | -24.67% | ||
| Current month | -28.48% | ||
| 1 month | -52.12% | ||
| 3 months | -66.37% | ||
| 6 months | -61.56% | ||
| Current year | -64.35% |
1 week
1.13
1.55
1 month
1.132.70
Current year
1.135.25
1 year
0.395.25
3 years
0.3913.78
5 years
0.3913.78
10 years
0.3913.78
| Managers | Title | Age | Since |
|---|---|---|---|
Mark Dybul
CEO | Chief Executive Officer | 60 | 18-01-22 |
Lester Russell
CTO | Chief Tech/Sci/R&D Officer | - | 23-08-20 |
Greg Duczynski
CTO | Chief Tech/Sci/R&D Officer | - | 15-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gregg Alton
BRD | Director/Board Member | 58 | 19-12-31 |
Avram Miller
BRD | Director/Board Member | - | 23-10-10 |
James Sapirstein
BRD | Director/Board Member | 63 | 18-03-05 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 0 M€ | +4.20% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 1.13 | -5.83% | 189,680 |
| 24-05-09 | 1.2 | -17.81% | 207,357 |
| 24-05-08 | 1.46 | -2.01% | 269,281 |
| 24-05-07 | 1.49 | +0.68% | 241,583 |
| 24-05-06 | 1.48 | -1.33% | 177,717 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotes
Renovaro Inc., formerly Renovaro BioSciences Inc., is a biotechnology company. The Company is engaged in the research and development of pharmaceutical and biological products for the treatment of cancer, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. The Company has a single product candidate as a potential cure for HIV, RENB-HV01, adding two additional pipeline candidates for HIV, RENB-HV12 and RENB-HV21, a pipeline for HBV, RENB-HB01, and with a significant into cancer immune therapies to address high unmet needs from difficult-to-treat solid tumors, RENB-DC11. RENB-HV-01 is a HIV autologous transplant with genetically modified cells. RENB-HV12 is a HIV therapeutic vaccine for potential long-term remission/cure. RENB-HV-21, a treatment for HIV with allogenic Natural Killer (NK) and Gamma Delta T-Cells (GDT). RENB-HB-01 is an HBV gene therapy candidate.
| 1st Jan change | Capi. | |
|---|---|---|
| -64.35% | 162M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- RENB Stock